- Home
- ZGM vs MURA Comparison
ZGM vs MURA Comparison
Compare ZGM & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGM
- MURA
- Stock Information
- Founded
- ZGM 2019
- MURA 2013
- Country
- ZGM Macau
- MURA Ireland
- Employees
- ZGM N/A
- MURA N/A
- Industry
- ZGM Professional Services
- MURA
- Sector
- ZGM Consumer Discretionary
- MURA
- Exchange
- ZGM Nasdaq
- MURA Nasdaq
- Market Cap
- ZGM 32.6M
- MURA 36.0M
- IPO Year
- ZGM 2025
- MURA N/A
- Fundamental
- Price
- ZGM $2.10
- MURA $2.09
- Analyst Decision
- ZGM
- MURA Buy
- Analyst Count
- ZGM 0
- MURA 2
- Target Price
- ZGM N/A
- MURA $6.00
- AVG Volume (30 Days)
- ZGM 64.6K
- MURA 112.3K
- Earning Date
- ZGM 01-06-2026
- MURA 11-06-2025
- Dividend Yield
- ZGM N/A
- MURA N/A
- EPS Growth
- ZGM 401.52
- MURA N/A
- EPS
- ZGM 0.17
- MURA N/A
- Revenue
- ZGM $3,620,780.00
- MURA N/A
- Revenue This Year
- ZGM N/A
- MURA N/A
- Revenue Next Year
- ZGM N/A
- MURA N/A
- P/E Ratio
- ZGM $12.36
- MURA N/A
- Revenue Growth
- ZGM 211.78
- MURA N/A
- 52 Week Low
- ZGM $1.90
- MURA $0.95
- 52 Week High
- ZGM $4.51
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- ZGM N/A
- MURA 51.21
- Support Level
- ZGM N/A
- MURA $2.06
- Resistance Level
- ZGM N/A
- MURA $2.10
- Average True Range (ATR)
- ZGM 0.00
- MURA 0.02
- MACD
- ZGM 0.00
- MURA -0.00
- Stochastic Oscillator
- ZGM 0.00
- MURA 50.00
About ZGM Zenta Group Company Limited Ordinary Shares
Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.